Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1
The recent emergence of a SARS-CoV-2 saltation variant, BA.2.87.1, which features 65 spike mutations relative to BA.2, has attracted worldwide attention. In this study, we elucidate the antigenic characteristics and immune evasion capability of BA.2.87.1. Our findings reveal that BA.2.87.1 is more s...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2024.2343909 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846138711737106432 |
|---|---|
| author | Sijie Yang Yuanling Yu Fanchong Jian Ayijiang Yisimayi Weiliang Song Jingyi Liu Peng Wang Yanli Xu Jing Wang Xiao Niu Lingling Yu Yao Wang Fei Shao Ronghua Jin Youchun Wang Yunlong Cao |
| author_facet | Sijie Yang Yuanling Yu Fanchong Jian Ayijiang Yisimayi Weiliang Song Jingyi Liu Peng Wang Yanli Xu Jing Wang Xiao Niu Lingling Yu Yao Wang Fei Shao Ronghua Jin Youchun Wang Yunlong Cao |
| author_sort | Sijie Yang |
| collection | DOAJ |
| description | The recent emergence of a SARS-CoV-2 saltation variant, BA.2.87.1, which features 65 spike mutations relative to BA.2, has attracted worldwide attention. In this study, we elucidate the antigenic characteristics and immune evasion capability of BA.2.87.1. Our findings reveal that BA.2.87.1 is more susceptible to XBB-induced humoral immunity compared to JN.1. Notably, BA.2.87.1 lacks critical escaping mutations in the receptor binding domain (RBD) thus allowing various classes of neutralizing antibodies (NAbs) that were escaped by XBB or BA.2.86 subvariants to neutralize BA.2.87.1, although the deletions in the N-terminal domain (NTD), specifically 15-23del and 136-146del, compensate for the resistance to humoral immunity. Interestingly, several neutralizing antibody drugs have been found to restore their efficacy against BA.2.87.1, including SA58, REGN-10933 and COV2-2196. Hence, our results suggest that BA.2.87.1 may not become widespread until it acquires multiple RBD mutations to achieve sufficient immune evasion comparable to that of JN.1. |
| format | Article |
| id | doaj-art-ddf249efe53945b0ac86117dd357f8ff |
| institution | Kabale University |
| issn | 2222-1751 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-ddf249efe53945b0ac86117dd357f8ff2024-12-07T04:40:18ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512024-12-0113110.1080/22221751.2024.2343909Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1Sijie Yang0Yuanling Yu1Fanchong Jian2Ayijiang Yisimayi3Weiliang Song4Jingyi Liu5Peng Wang6Yanli Xu7Jing Wang8Xiao Niu9Lingling Yu10Yao Wang11Fei Shao12Ronghua Jin13Youchun Wang14Yunlong Cao15Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of ChinaBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of ChinaBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of ChinaBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaBeijing Ditan Hospital Capital Medical University, Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaBeijing Ditan Hospital Capital Medical University, Beijing, People’s Republic of ChinaChangping Laboratory, Beijing, People’s Republic of ChinaBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People’s Republic of ChinaThe recent emergence of a SARS-CoV-2 saltation variant, BA.2.87.1, which features 65 spike mutations relative to BA.2, has attracted worldwide attention. In this study, we elucidate the antigenic characteristics and immune evasion capability of BA.2.87.1. Our findings reveal that BA.2.87.1 is more susceptible to XBB-induced humoral immunity compared to JN.1. Notably, BA.2.87.1 lacks critical escaping mutations in the receptor binding domain (RBD) thus allowing various classes of neutralizing antibodies (NAbs) that were escaped by XBB or BA.2.86 subvariants to neutralize BA.2.87.1, although the deletions in the N-terminal domain (NTD), specifically 15-23del and 136-146del, compensate for the resistance to humoral immunity. Interestingly, several neutralizing antibody drugs have been found to restore their efficacy against BA.2.87.1, including SA58, REGN-10933 and COV2-2196. Hence, our results suggest that BA.2.87.1 may not become widespread until it acquires multiple RBD mutations to achieve sufficient immune evasion comparable to that of JN.1.https://www.tandfonline.com/doi/10.1080/22221751.2024.2343909SARS-CoV-2neutralizing antibodieshumoral immunityimmune escapesaltation variant |
| spellingShingle | Sijie Yang Yuanling Yu Fanchong Jian Ayijiang Yisimayi Weiliang Song Jingyi Liu Peng Wang Yanli Xu Jing Wang Xiao Niu Lingling Yu Yao Wang Fei Shao Ronghua Jin Youchun Wang Yunlong Cao Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1 Emerging Microbes and Infections SARS-CoV-2 neutralizing antibodies humoral immunity immune escape saltation variant |
| title | Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1 |
| title_full | Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1 |
| title_fullStr | Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1 |
| title_full_unstemmed | Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1 |
| title_short | Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1 |
| title_sort | antigenicity assessment of sars cov 2 saltation variant ba 2 87 1 |
| topic | SARS-CoV-2 neutralizing antibodies humoral immunity immune escape saltation variant |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2024.2343909 |
| work_keys_str_mv | AT sijieyang antigenicityassessmentofsarscov2saltationvariantba2871 AT yuanlingyu antigenicityassessmentofsarscov2saltationvariantba2871 AT fanchongjian antigenicityassessmentofsarscov2saltationvariantba2871 AT ayijiangyisimayi antigenicityassessmentofsarscov2saltationvariantba2871 AT weiliangsong antigenicityassessmentofsarscov2saltationvariantba2871 AT jingyiliu antigenicityassessmentofsarscov2saltationvariantba2871 AT pengwang antigenicityassessmentofsarscov2saltationvariantba2871 AT yanlixu antigenicityassessmentofsarscov2saltationvariantba2871 AT jingwang antigenicityassessmentofsarscov2saltationvariantba2871 AT xiaoniu antigenicityassessmentofsarscov2saltationvariantba2871 AT linglingyu antigenicityassessmentofsarscov2saltationvariantba2871 AT yaowang antigenicityassessmentofsarscov2saltationvariantba2871 AT feishao antigenicityassessmentofsarscov2saltationvariantba2871 AT ronghuajin antigenicityassessmentofsarscov2saltationvariantba2871 AT youchunwang antigenicityassessmentofsarscov2saltationvariantba2871 AT yunlongcao antigenicityassessmentofsarscov2saltationvariantba2871 |